Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
Abstract
The present invention relates to the discovery, identification and characterization of a novel tumor suppressor gene designated PARIS-1. The invention includes nucleotide sequences of the PARIS-1 gene and amino acid sequences of its encoded protein product(s), as well as fragments, derivatives and analogs thereof. The invention also includes the production of PARIS-1 proteins, fragments and derivatives and of antibodies specific for PARIS-1 gene products. The invention further comprises agents and compositions which can modulate the expression of PARIS-1 or PARIS-1 expression products to effect the proliferation of cells which express PARIS-1. One particular embodiment comprises agents and compounds which can slow or ablate the proliferation of prostate tumor cells.
Claims
exact text as granted — not AI-modified1 . An antibody which can immunospecifically bind a PARIS-1 protein or fragment thereof.
2 . The antibody of claim 1 which is a monoclonal antibody.
3 . A composition comprising an amount of PARIS-1 protein, or a fragment thereof, which can effectively modulate cell proliferation and a pharmaceutically acceptable carrier.
4 . The composition of claim 3 , wherein the PARIS-1 protein is human PARIS-1
5 . A composition comprising an amount of an antigen binding fragment or derivative of an antibody immunospecific for PARIS-1 protein and a pharmaceutically acceptable carrier.
6 . A method for decreasing the rate of proliferation of a cell which expresses PARIS-1 in a subject comprising administering an amount of an agent which effectively modulates PARIS-1 activity to modulate cell proliferation.
7 . The method of claim 6 , wherein the agent promotes translation of mRNA transcripts which encode PARIS-1.
8 . The method of claim 6 , wherein the agent comprises a nucleic acid encoding a PARIS-1 protein, a nucleic acid encoding a PARIS-1 derivative or analog that is active in inhibiting cell proliferation.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.